LinkedIn Icon
September 26-28 2017
The Seaport Hotel and WTC, Boston, MA

Day One
Wednesday September 27 2017

Day Two
Thursday September 28 2017

Registration & Networking

Chair’s Opening Remarks

  • Jonathan Davis Protein Design & Principal Scientist, Innovative Protein Engineer & Drug Designer, Bristol-Myers Squibb

Clinical Development of Bispecific DART® Molecules – Experiences to Date

  • Paul Moore Vice President, Cell Biology & Immunology, MacroGenics


  • Strategies and dosing paradigms employed to support dosing of DART molecules redirecting T-cell killing of liquid and solid tumors
  • PK/PD relationship of MGD010, a DART molecule targeting blockade of B-cell activation
  • Demonstration of on-target cellular binding and associated mechanism of action

Preclinical and Clinical Development of a Novel Biparatopic HER2 Antibody in Low to High HER2-Expressing Cancers


  • Safety and preliminary efficacy data for the dose escalation of ZW25 in Phase 1 clinical trial
  • Understanding the mechanism of biparatopic binding and contributions to ZW25’s mechanisms of action
  • Importance of bispecific format selection in lead optimization to be discussed

Morning Refreshments & Networking

Generating & Validating Innovative Formats Across Disease Indications

11.00 Bispecific Antibody Technologies & Their Applications at Chugai

  • Sharing information of technologies for bispecific antibody generation in our company
  • Showing how to screen and generate bispecific antibodies for clinical use, and introducing actual clinical results of bispecific antibody
  • Presenting novel approach of sweeping antibody with biparatopic antibody to eliminate soluble antigen in blood stream

Hirotake Shiraiwa, Group manager, Research Division, Chugai Pharmaceutical

11.30 Next Generation ADAPTIR™ Bispecific Antibody Candidates Demonstrating Potent Immune Activation

Full details to be confirmed



12.00 Lunch & Networking

Discovering Approaches to Deliver a Potent Anti-Tumor Immune Response

13.00 Employing DART® and TRIDENT™ Platforms for Dual Checkpoint Blockade or Tumor Anchored Immune Co-Stimulation

  • Development of MGD013 for simultaneous blockade of the PD-1 and LAG3 to maximize reversal of T-cell exhaustion
  • Varying binding valency to modulate relative inhibition of PD-1 and CTLA4 in a single molecule
  • Optimizing molecular design to support tumor anchored immune costimulation via CD137 pathway

Syd Johnson, Vice President, Antibody Engineering, MacroGenics

13.30 Insights into the Optimal Combination Strategies to Convert Cold to Hot Tumors

  • Investigating the solid tumor microenvironment in specific relation to immunotherapies
  • Highlighting existing and emerging bispecific CAR T-cell therapies for solid tumors and their ability to convert non-inflamed solid tumors to inflamed
  • Discussing combination strategies to advance the efficacy of immunotherapy

Prasad Adusumilli, Deputy Chief, Thoracic Service, MSKCC

Implementing High Throughput Approaches to Enhance Development

11.00 Automated High Throughput Generation of Bispecific Antibodies via Controlled Fab-arm Exchange

  • Enabling the high throughput generation of large libraries of bispecific antibodies for functional screening through the automation of the post-production exchange process
  • Insights into the unattended process, consisting of liquid handling to build bispecific matrices, temperature controlled exchange, reductant removal and quantification
  • Investigating the design of the process and a proof-of-concept studies generating bispecifics

Arnout Gerritsen, Associate Director, Assay & Bio-Analytical Science, Genmab

11.30 Patient Directed Bispecific Target Discovery by High Throughput Functional Screening

  • Facilitating an unbiased approach to target ID and validation through grid screening of large numbers of bispecific antibody combinations
  • Combining antibody discovery capabilities, a novel bispecific screening format and high throughput flow cytometry or imaging to enable the screening of thousands of bispecific antibodies to hundreds of antigen combinations
  • Describing an example application and target pair discovery to demonstrate the capabilities of this approach

Helen Finney, Director, Functional Screening, UCB

12.00 Lunch & Networking

Optimizing Preclinical Development to Bridge the Gap to the Clinic

13.00 Improving the Predictability of Preclinical Models to Bridge the Gap to Clinical Application

  • Analysing early clinical data and using these insights to enhance the preclinical development of bispecifics
  • Investigating the use of humanized and syngeneic models and their role in validating the efficacy of complex multispecific therapeutics
  • How can preclinical models be utilized most effectively?

Christopher Murriel, Senior Scientist ll, OncoMed Pharmaceuticals

13.30 Engineering BiTE® Antibody Constructs For Improved Pharmacokinetics and Pharmacodynamics

  • BiTE® antibody constructs are clinically validated for the treatment of hematological malignancies
  • Generating BiTE® antibody constructs in different formats and assessed their pharmacokinetic properties and ability to deplete target cells in tissues
  • Demonstrating antibody-like PK with highly potent target cell ablation in vivo, offering a promising approach for the treatment of additional cancer indications

Mike Giffin, Scientist, Amgen

Afternoon Refreshments & Networking

Beyond Oncology: Applications of Multispecific Therapeutics in Diverse Disease Indications

Bispecific Antibodies as Cross-Protective Filovirus Immunotherapeutics

  • Jonathan Lai Associate Professor, Albert Einstein College of Medicine


  • Understanding the biology of filoviruses, including Ebola virus and Marburg virus, which cause severe hemorrhagic fever with high mortality
  • Antibodies are a viable therapeutic platform, but mAbs with broad activity are rare
  • Investigating how bispecific antibody engineering has been utilized to develop novel cross-protective therapies

Novel Bispecific Antibody as a Potential Treatment for Alpha-Dystroglycanopathy


  • Pioneering bispecific therapeutics for the treatment of alpha-dystroglycanopathy, a rare form of congenital muscular dystrophy, caused by mutations in anyone of the 18 genes identified so far that are involved in the biosynthesis of the unique O-glycan on alpha-dystroglycan
  • Examining the design of a novel bispecific antibody that can restore the broken linkage between laminin-2 and dystroglycan as a potential therapy for alpha-dystroglycanopathies
  • Sharing in vivo data generated to support this therapeutic concept

Chair’s Closing Remarks

  • Jonathan Davis Protein Design & Principal Scientist, Innovative Protein Engineer & Drug Designer, Bristol-Myers Squibb